InflaRx Shares Surge 30% on Q2 Update and Pipeline Milestones
By ATTN Desk · Editorial oversight: Sean Han
InflaRx N.V. (NASDAQ: IFRX)
InflaRx N.V. is a clinical-stage biopharmaceutical company applying proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize inhibitors of the complement activation factor C5a and its receptor C5aR. Complement C5a is an inflammatory mediator implicated in autoimmune and other inflammatory diseases. InflaRx’s lead monoclonal antibody, vilobelimab (GOHIBIC), and its small-molecule C5aR inhibitor program are central to its pipeline.
Corporate Structure
InflaRx was founded in 2007 and maintains offices in Jena and Munich, Germany, as well as Ann Arbor, Michigan, USA. The company employs between 51 and 200 people, including research scientists, clinical development teams, and commercial support functions. As a public company listed on NASDAQ under the ticker IFRX, InflaRx complies with U.S. reporting requirements while retaining its European headquarters.
Biopharmaceuticals by little plant
Recent Developments and News
On August 7, 2025, InflaRx published its second-quarter 2025 financial results and provided a business update. Key updates include:
- Initiation of enrollment in the BARDA-funded JUST BREATHE Phase 2 platform study of vilobelimab in acute respiratory distress syndrome.
- Announcement that topline data from the INF904 Phase 2a trial in chronic spontaneous urticaria and hidradenitis suppurativa are expected by the end of September to early November 2025.
- Reporting of favorable Phase 1/2 data by Staidson BioPharmaceuticals for the InflaRx-licensed anti-C5a antibody BDB-001 in ANCA-associated vasculitis, with plans to advance into Phase 3.
- Notification that unblinding of the suspended Phase 3 pyoderma gangrenosum trial is expected to occur later in 2025.
InflaRx will participate in the following investor events in September 2025:
- September 4, 2025: Cantor Global Healthcare Conference (fireside chat at 9:10 AM ET), New York, NY
- September 8–9, 2025: Unite for Sepsis Symposium session “Modulating the Immune System to Help, Not Hurt,” Chicago, IL
- September 9, 2025: H.C. Wainwright 27th Annual Global Investment Conference (corporate presentation at 3:00 PM ET), New York, NY
Financial and Strategic Aspects
| Metric | Value |
|---|---|
| Stock Price (2025-08-29) | $1.5295 |
| Daily Change | +30.73 % |
| Trading Volume | 1,507,906 |
| Exchange | NASDAQ |
| Ticker | IFRX |
Key SEC filings in 2025 include:
- 6-K filed June 27, 2025: Notification of change in independent auditor from EY GmbH & Co. KG to KPMG, effective for the fiscal year ending December 31, 2025.
- 6-K filed July 14, 2025: Notice from Nasdaq regarding bid price below $1.00, with a compliance period until January 7, 2026; a potential transfer to the Nasdaq Capital Market provides an additional 180 days if needed.
- 6-K filed August 7, 2025: General report of foreign issuer matters; detailed financial metrics were not included in the extracted content.
Market Position and Industry Context
InflaRx operates in the biotech research sector, focusing on complement-mediated inflammatory pathways. Its pipeline spans acute indications such as ARDS (GOHIBIC) and chronic autoimmune conditions (INF904, BDB-001). A U.S. Emergency Use Authorization for GOHIBIC in COVID-19 was granted in April 2023 under Section 564(b)(1), valid for the duration of the public health emergency. In Europe, commercial partnering options for its pipeline candidates are under consideration. Competitive pressures stem from other complement inhibitors and broader anti-inflammatory platforms, while strategic collaborations (e.g., with BARDA and Staidson BioPharmaceuticals) support development pathways.
tl;dr
As of August 29, 2025, InflaRx’s stock (NASDAQ: IFRX) stands at $1.5295, up 30.73 % on heavy volume. Second-quarter results were released on August 7, 2025, alongside updates on the JUST BREATHE Phase 2 trial and INF904 Phase 2a data expected by late September to early November 2025. A Nasdaq minimum-bid-price notice grants InflaRx until January 7, 2026, to regain compliance. Upcoming investor engagements include sessions on September 4, 8–9, and 9, 2025.